Article | December 27, 2022

Our Investments, Your Outcomes: Shortening The Pharmaceutical Lifecycle To Provide Better, Faster Cures

Source: Seeq Corporation

By Petter Moree

Pharmaceutical Production GettyImages-1212679721

The life sciences industry is booming, valued at 1.3 trillion dollars, with approximately 300 global companies delivering over 20,000 different lifesaving treatments, personalized medicines, gene therapies, and cures to patients annually. It may take just a moment for a patient to pop a pill or receive an injection, but these treatments typically require decades of research and billions of dollars to develop and bring to market. Drugs are often prepared for consumption by contract development manufacturing organizations (CDMOs) under stringent Food and Drug Administration (FDA) regulations.

While the drug development cycle is lengthy, the COVID-19 vaccine is a recent and notable exception. Requiring just over one year to develop and bring to market, its distribution was, and continues to be, a remarkable feat. We are striving to normalize this timeline and enable life sciences companies to shorten development and distribution cycles so patients around the world can access cures whenever there’s a need.

Explore three areas where investments in the life sciences industry are improving outcomes and shortening development cycles.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online